This morning we read a press release issued by Valeritas (NASDAQ: VLRX) which contained the following passage;
“Achievement of glycemic targets occurred in 2/3 of patients and patient reported hypoglycemia was decreased by study end utilizing this therapeutic approach to insulin management.”
It seems that Valeritas has jumped onto the self-reported bandwagon. Yep just like our friends at OneDrop, the folks at Valeritas have conveniently forgotten that self-reported data is basically meaningless and proof of nothing. Given this fondness for meaningless data we think these two companies should hook up. Heck think of the possibilities, think of . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.